Clinical Trial Details
| Trial ID: | L1875 |
| Source ID: | NCT04221360 |
| Associated Drug: | Ckd-375 |
| Title: | A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375 |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Type2 Diabetes Mellitus |
| Interventions: | DRUG: CKD-375|DRUG: D390 |
| Outcome Measures: | Primary: Cmax of D390 and CKD-375, Maximum plasma concentration of D390 and CKD-375, 0(predose)~48 hours|AUClast of D390 and CKD-375, Area under the plasma concentration-time curve to last concentration of D390 and CKD-375, 0(predose)~48 hours | Secondary: AUCinf of D390 and CKD-375, Area under the plasma concentration-time curve from zero to infinity concentration of D390 and CKD-375, 0(predose)~48 hours|Tmax of D390 and CKD-375, Time to maximum plasma concentration of D390 and CKD-375, 0(predose)~48 hours|t1/2 of D390 and CKD-375, Half-life of D390 and CKD-375, 0(predose)~48 hours|Vd/F of D390 and CKD-375, Apparent volume of distribution of D390 and CKD-375, 0(predose)~48 hours|CL/F of D390 and CKD-375, Apparent clearance of D390 and CKD-375, 0(predose)~48 hours |
| Sponsor/Collaborators: | Sponsor: Chong Kun Dang Pharmaceutical |
| Gender: | ALL |
| Age: | ADULT |
| Phases: | PHASE1 |
| Enrollment: | 26 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2020-01-29 |
| Completion Date: | 2020-06-08 |
| Results First Posted: | |
| Last Update Posted: | 2020-01-09 |
| Locations: | Yonsei University Severance Hospital, Soeul, Korea, Republic of |
| URL: | https://clinicaltrials.gov/show/NCT04221360 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|